北京市春立正达医疗器械股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中 国公司。该公司主要产品包括关节假体产品、脊柱类植入产品、创伤类产品、运动医学类产品、富血小 板血浆（PRP）产品、口腔类产品、手术机器人产品。关节假体产品涵盖髋、膝、肩、肘四大人体关 节。该公司产品销往国内外市场。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2月27日南向资金增持16.82万股春立医疗（01858.HK）。近5个交易日中，获南向资金 增持的有3天，累计净增持15.2万股。近20个交易日中，获南向资金减持的有12天，累计净减持112.97万 股。截至目前，南向资金持有春立医疗（01858.HK）4121.68万股，占公司已发行普通股的43.31%。 ...

来源：新浪证券-红岸工作室 2月25日，春立医疗跌0.49%，成交额3254.20万元。两融数据显示，当日春立医疗获融资买入额765.16 万元，融资偿还494.07万元，融资净买入271.09万元。截至2月25日，春立医疗融资融券余额合计 7301.17万元。 融资方面，春立医疗当日融资买入765.16万元。当前融资余额7300.72万元，占流通市值的1.14%，融资 余额超过近一年90%分位水平，处于高位。 融券方面，春立医疗2月25日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量200.00股，融券余额4458.00元，超过近一年70%分位水平，处于较高位。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 资料显示，北京市春立正达医疗器械股份有限公司位于北京市通州区通州经济开发区南区鑫觅西二路10 号，成立日期1998年2月12日，上市日期2021年12月30日，公司主营业务涉及北京市春 ...

分红方面，春立医疗A股上市后累计派现4.40亿元。近三年，累计派现3.90亿元。 机构持仓方面，截止2025年9月30日，春立医疗十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股295.85万股，为新进股东。中欧景气精选混合A（020876）位居第五大流通股东，持股 283.26万股，为新进股东。平安低碳经济混合A（009878）位居第八大流通股东，持股210.00万股，相 比上期减少167.00万股。南方医药保健灵活配置混合A（000452）退出十大流通股东之列。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 融券方面，春立医疗2月24日融券偿还200.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量200.00股，融券余额4480.00元，超过近一年70%分位水平，处于较高位。 资料显示，北京市春立正达医疗器械股份有限公司位于北京市通州区通州经济开发区南区鑫觅西二路10 号，成立日期19 ...

Core Viewpoint - Southbound funds increased their holdings in Chuangli Medical (01858.HK) by 61,000 shares on February 13, 2023, despite a net reduction of 338,800 shares over the past five trading days [1] Group 1: Southbound Fund Activity - In the last five trading days, there were three days of net reductions in holdings by southbound funds, totaling 338,800 shares [1] - Over the past 20 trading days, there were ten days of net reductions, amounting to 246,800 shares [1] - As of now, southbound funds hold 41,125,800 shares of Chuangli Medical, representing 43.21% of the company's issued ordinary shares [1] Group 2: Company Overview - Beijing Chuangli Zhengda Medical Device Co., Ltd. primarily engages in the research, development, production, and sales of implantable orthopedic medical devices [1] - The company's main products include joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [1] - Joint prosthetics cover four major human joints: hip, knee, shoulder, and elbow, with products sold in both domestic and international markets [1]

Core Viewpoint - Spring Medical has experienced a decline in stock price and trading volume, with a notable drop in recent trading days, indicating potential investor concerns about the company's performance and market position [1]. Group 1: Company Overview - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, is based in Tongzhou District, Beijing, and specializes in the research, production, and sales of implantable orthopedic medical devices [1]. - The company's main products include joint prosthetics (hip, knee, shoulder, elbow) and a full range of spinal implant products [1]. - The revenue composition of the company is predominantly from medical device products at 99.89%, with other sources contributing 0.11% [1]. Group 2: Financial Performance - For the period from January to September 2025, Spring Medical reported a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, which is a significant increase of 213.21% [2]. - Since its A-share listing, the company has distributed a total of 440 million yuan in dividends, with 390 million yuan distributed over the past three years [3]. Group 3: Market Activity - As of February 12, 2023, Spring Medical's stock price was 22.40 yuan per share, with a market capitalization of 8.592 billion yuan [1]. - The stock has seen a year-to-date decline of 1.20%, a 5-day drop of 3.16%, an 18.13% decrease over the past 20 days, and a 12.98% decline over the last 60 days [1]. - The company has experienced a net outflow of 1.0456 million yuan in principal funds, with large orders accounting for 3.27% of purchases and 8.11% of sales [1].

融券方面，春立医疗2月10日融券偿还400.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量400.00股，融券余额9184.00元，超过近一年80%分位水平，处于高位。 来源：新浪证券-红岸工作室 2月10日，春立医疗跌0.17%，成交额2656.60万元。两融数据显示，当日春立医疗获融资买入额419.19 万元，融资偿还272.99万元，融资净买入146.20万元。截至2月10日，春立医疗融资融券余额合计 5000.10万元。 融资方面，春立医疗当日融资买入419.19万元。当前融资余额4999.18万元，占流通市值的0.75%，融资 余额超过近一年90%分位水平，处于高位。 分红方面，春立医疗A股上市后累计派现4.40亿元。近三年，累计派现3.90亿元。 机构持仓方面，截止2025年9月30日，春立医疗十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股295.85万股，为新进股东。中欧景气精选混合A（020876）位居第五大流通股东，持股 283.26万股，为新进股东。平安低碳经济混合A（009878）位居第八大流通股东，持股210.00万股，相 比上期减少167 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 北京市春立正达医疗器械股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中 国公司。该公司主要产品包括关节假体产品、脊柱类植入产品、创伤类产品、运动医学类产品、富血小 板血浆（PRP）产品、口腔类产品、手术机器人产品。关节假体产品涵盖髋、膝、肩、肘四大人体关 节。该公司产品销往国内外市场。 证券之星消息，2月10日南向资金减持3.1万股春立医疗（01858.HK）。近5个交易日中，获南向资金减 持的有4天，累计净减持78.95万股。近20个交易日中，获南向资金减持的有11天，累计净减持90.12万 股。截至目前，南向资金持有春立医疗（01858.HK）4144.63万股，占公司已发行普通股的43.55%。 ...

来源：新浪证券-红岸工作室 2月9日，春立医疗跌0.35%，成交额3498.88万元。两融数据显示，当日春立医疗获融资买入额524.38万 元，融资偿还376.73万元，融资净买入147.65万元。截至2月9日，春立医疗融资融券余额合计4854.82万 元。 融资方面，春立医疗当日融资买入524.38万元。当前融资余额4852.98万元，占流通市值的0.73%，融资 余额超过近一年90%分位水平，处于高位。 资料显示，北京市春立正达医疗器械股份有限公司位于北京市通州区通州经济开发区南区鑫觅西二路10 号，成立日期1998年2月12日，上市日期2021年12月30日，公司主营业务涉及北京市春立正达医疗器械 股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中国公司。该公司主要产品 为关节假体产品及脊柱类植入产品。关节假体产品涵盖髋、膝、肩、肘四大人体关节。脊柱类植入产品 为脊柱内固定系统的全系列产品组合。该公司的产品出口至亚洲、南美洲、非洲、大洋洲及欧洲等多个 国家和地区。主营业务收入构成为：医疗器械产品99.89%，其他(补充)0.11%。 截至9月30日，春立医疗股东户数6164.00，较上 ...

Core Viewpoint - Southbound funds increased their holdings in Chuangli Medical (01858.HK) by 12,700 shares on February 9, indicating a fluctuating interest from these investors in the company [1] Group 1: Southbound Fund Activity - Over the past five trading days, there were three days of net reductions in holdings by southbound funds, totaling a net decrease of 674,000 shares [1] - In the last twenty trading days, there were ten days of net reductions, with a cumulative net decrease of 769,000 shares [1] - Currently, southbound funds hold 41,477,300 shares of Chuangli Medical, accounting for 43.59% of the company's total issued ordinary shares [1] Group 2: Company Overview - Beijing Chuangli Zhengda Medical Device Co., Ltd. specializes in the research, development, production, and sales of implantable orthopedic medical devices [1] - The company's main products include joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [1] - Joint prosthetics cover four major human joints: hip, knee, shoulder, and elbow, with products sold in both domestic and international markets [1]

Core Viewpoint - Spring Medical, a leading domestic orthopedic medical device manufacturer, focuses on the research, production, and sales of implantable orthopedic medical devices, including dental metal and invisible orthodontics, and is currently in the design and inspection phase for customized porous tantalum dental implants [2][3]. Company Overview - Spring Medical is located in Tongzhou District, Beijing, and was established on February 12, 1998. The company went public on December 30, 2021, and primarily engages in the research, production, and sales of implantable orthopedic medical devices [7]. - The main products include joint prosthetics and spinal implant products, covering four major human joints: hip, knee, shoulder, and elbow, as well as a full range of spinal internal fixation systems [8]. Financial Performance - For the period from January to September 2025, Spring Medical achieved operating revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a year-on-year increase of 213.21% [8]. - The company has distributed a total of 440 million yuan in dividends since its A-share listing, with 390 million yuan distributed over the past three years [8]. Industry Position - Spring Medical has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is the highest honor for small and medium-sized enterprises in China, indicating strong innovation capabilities and high market share [3]. - The company is classified under the pharmaceutical and biological industry, specifically in medical devices and consumables, and is involved in various concept sectors including dental medical, robotics, and innovative enterprises [8]. Shareholder Information - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited as the fourth largest shareholder with 2.9585 million shares, and new entrants such as China Europe Economic Selection Mixed A and Ping An Low Carbon Economy Mixed A [9].